Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

Guo, Qing-Long; Dai, Xing-Liang; Yin, Meng-Yuan; Cheng, Hong-Wei; Qian, Hai-Sheng; Wang, Hua; Zhu, Dao-Ming; Wang, Xian-Wen

doi:10.1186/s40779-022-00386-z

Military Medical Research

Table 1 Summary of modality and sonosensitizers used for SDT therapy in glioblastoma

From: Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

Modality	Sonosensitizers	Cell line	US power	References
Traditional SDT	5-ALA	RG2	1 MHz, 0.5 W/cm², 3 min	[44]
	5-ALA	U87/U251	3 MHz, 2 W/cm², 3 min	[45]
	5-ALA	C6	1.06 MHz, 0.33–8 W/cm²	[47]
	5-ALA	C6/U87	1.1 MHz, 10 W/cm², 3 min	[48]
	5-ALA	C6	1.04 MHz, 10 W/cm², 5 min	[50]
	5-ALA	C6	1 MHz, 2.65 W/cm², 20/40/60 min	[51]
	Fluorescein	C6	2–6 W/cm², 20 min	[53]
	Rose Bengal	C6	1 MHz, 25 W/cm², 5 min	[54]
	HMME	C6	1 MHz, 0.5 W/cm², 2 min	[56]
	HMME	C6	1 MHz, 1 W/cm², 1 min	[55]
	HMME	C6	0.5 MHz, 1 W/cm², 1 min	[58]
	HMME	C6	1 MHz, 0.5 W/cm², 2 min	[38]
	HMME	C6	1 MHz, 0.5 W/cm², 2 min	[59]
	HMME	C6	1 MHz, 0.5 W/cm², 90 s	[60]
	DVDMS	U87	0.97 MHz, 3 min	[61]
	DVDMS	U118/U87	1 MHz, 0.5 W/cm², 1 min/3 min	[62]
	DVDMS	U373	1 MHz, 0.45 W/cm², 1 min	[63]
	Photofrin	GSC/U251	1 MHz, 0.5 W/cm², 1 min	[64]
	Photofrin	GSC	1 MHz, 0.5 W/cm², 2 min	[65]
	Photolon	C6	0.88 MHz, 0.2/0.4/0.7 W/cm², 1 min	[67]
	5-ALA/PPIX/talaporfin	C6/U87	1 MHz, 0.16 W/cm², 1 min	[52]
	TiO₂	U251	1 MHz, 1 W/cm², 30 s	[70]
Improved SDT	iRGD-Lipo-DVDMS	C6	1 MHz, 1 W/cm², 1 min	[72]
	DVDMS-Mn-LPs	U87	0.5 MHz, 0.5 W/cm², 5 min	[73]
	MnO₂@Tf-ppIX	C6	1 MHz, 1.5 W/cm², 3 min	[74]
	PpIX@HMONs-MnOxRGD	U87	1 MHz, 1.5 W/cm², 1 min	[75]
Combination therapy	HPPH@PAA-NMe³⁺	U87	3.3 MHz, 0.5 W/cm², 30 min	[76]
	Photolon	C6	1 MHz, 0.4/0.7/1.0 W/cm², 10 min	[66]
	HMME + TMZ	C6	1 MHz, 1 W/cm², 0–24 h	[57]
	AlPcS_2a + BLM	F98	1 MHz, 3 min	[68]
	AlPcS_2a + BLM	F98	1 MHz, 0–0.6 W/cm², 3 min	[69]
	TiO₂ + anti-EGFR antibody	U87MG/U87MGde2–7	1 MHz, 1.8 W/cm², 1 min	[71]
	IR780/PTX	U87	1 MHz, 0.2–0.4 W/cm², 3 min	[77]
	Dox-pp-lipo	U87	1 MHz, 0.3 W/cm², 3 min	[78]
	ACHL	GL261	1 MHz, 1 W/cm², 1 min	[79]
	5-ALA	SNB19/U87	1 MHz, 1 W/cm², 2 W/cm², 2 min	[46]
	5-ALA	F98	4000/500 J, 20/18 W, 240/30 s	[49]
	HCM NAs	U87	1 W/cm²	[80]
	5-ALA	F98	500 J, 18 W, 30 s	[81]

5-ALA 5-aminolevulinic acid, HMEE hematoporphyrin mono-methyl ether, DVDMS sino-porphyrin sodium, ppIX protoporphyrin IX, iRGD cyclic arginine-glycine-aspartic pentapeptide, Tf transferrin, HPPH 3-(1′-Hexyloxy) ethyl-3-devinylpyropheophorbide, PAA-NMe₃⁺ cationic polyacrylamide nanoparticles, TMZ temozolomide, AlPcS_2a aluminum phthalocycanine disulfonate, BLM bleomycin, EGFR epithelial growth factor receptor, PTX paclitaxel, DOX doxorubicin, Lipo liposome, ACHL angiopep-2-modified liposomes, HCM NAs manganese ion (Mn²⁺)-chelated human serum albumin (HSA)-chlorin e6 (Ce6) nanoassemblies

Back to article page

ISSN: 2054-9369

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com